February 22, 2021 -- Amyris, in partnership with the Infectious Disease Research Institute (IDRI), has released preliminary data from a preclinical study of its RNA COVID-19 vaccine platform.
Amyris announced that it entered into a collaboration agreement and exclusive license with the IDRI in October 2020 to advance a novel RNA vaccine platform, including the development of a COVID-19 vaccine.
Preliminary data from the study of a self-adjuvanting RNA COVID-19 vaccine candidate developed using IDRI's nanostructured lipid carrier (NLC) vaccine platform demonstrated a significant level of antibody production against the SARS-CoV-2 spike protein.
Manufacturing of the vaccine is possible with easily sourced components, including Amyris' sustainable sugarcane squalene, which would replace the use of traditional shark-derived squalene in vaccines. The Amyris-IDRI platform's manufacturing process is also designed with a well-established oil-in-water emulsion technology.
The Amyris-IDRI COVID-19 vaccine candidate can be stored at refrigerator temperatures for prolonged periods and for several months at room temperature, potentially improving vaccine distribution.
The Amyris-IDRI vaccine platform will be advancing to phase I clinical trials with the support of the Portuguese government and other partners.
Copyright © 2021 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
